GSK plc has completed the acquisition of IDRx, Inc. on February 24, 2025, for up to $1.15 billion, aimed at enhancing its cancer treatment pipeline with the investigational drug IDRX-42.
AI Assistant
GSK PLC
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.